西班牙国家注册研究:儿童长QT综合征的临床结局与治疗
β受体阻滞剂使用率达92.4%,左心交感神经去神经术与>80%无心律失常生存相关,支持基因型与QTc指导的管理策略。
要点
- 儿童长QT综合征主要心律失常事件少见(3.8%),多集中于高危基因型、QTc≥550 ms或极早发病者。
- β受体阻滞剂为基石治疗(使用率92.4%),左心交感神经去神经术和高危患者选择性ICD植入可考虑。
- 胎儿/新生儿心动过缓(5.1%)与高危基因型及不良结局相关。
核心结论
- 在该全国儿童长QT综合征队列中,主要心律失常事件不常见,集中于恶性基因型、QTc显著延长和极早发病(尤其是胎儿或新生儿心动过缓)的儿童。
- 数据支持当前基因型与QTc指导的管理策略,以β受体阻滞剂为基石,高危患者选择性使用左心交感神经去神经术和ICD。
主要发现
- 86.5%检出致病/可能致病性变异,主要位于KCNQ1、KCNH2或SCN5A;5.7%携带高危基因型(Jervell-Lange-Nielsen综合征、钙调蛋白病、CACNA1C/Timothy综合征)。
- 中位随访6年,14例(3.8%)发生主要心律失常事件,主要见于高危基因型、QTc≥550 ms或极早发病者;LQT1-3且QTc<500 ms者事件罕见。
- 胎儿/新生儿心动过缓占5.1%,与高危基因型及不良结局相关。
- 33例(8.9%)植入ICD,其中10例(30%)接受适当治疗,8例(24%)出现并发症。
- 33例(8.9%)行左心交感神经去神经术,主要用于高危患者,与>80%无心律失常生存相关且无严重并发症。
关键数值与推荐
- 主要心律失常事件定义为心源性猝死、心脏骤停复苏成功或ICD适当治疗。
- β受体阻滞剂处方率为92.4%。
临床怎么用
- 对儿童长QT综合征应进行基因检测和QTc评估以风险分层,β受体阻滞剂作为基础治疗。
- 高危基因型、QTc≥550 ms或极早发病(尤其胎儿/新生儿心动过缓)者应考虑强化治疗,包括左心交感神经去神经术或ICD植入。
- ICD植入需权衡适当治疗获益与并发症风险(本队列并发症率24%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Congenital long QT syndrome (LQTS) is a heterogeneous disorder in which genotype and QTc duration modulate the risk of major arrhythmic events (MAEs), but contemporary paediatric outcome data remain limited. This study aimed to characterize clinical features, management strategies, and predictors of MAEs in a nationwide paediatric LQTS cohort. METHODS: This retrospective multicentre study analysed children (<18 years) diagnosed with LQTS across 30 tertiary centres (2004-24) using 2022 European Society of Cardiology criteria. MAEs were defined as sudden cardiac death, aborted cardiac arrest, or appropriate implantable cardioverter-defibrillator (ICD) therapy. RESULTS: The cohort included 371 children (58% male; median diagnosis age 6.0 years; interquartile range .25-11 years). Pathogenic/likely pathogenic variants were identified in 86.5%, mainly in KCNQ1, KCNH2, or SCN5A, while 5.7% harboured high-risk genotypes (Jervell-Lange-Nielsen, calmodulinopathies, CACNA1C/Timothy). Beta-blockers were prescribed in 92.4%. Over a median 6-year follow-up, 14 children (3.8%) experienced MAEs, which occurred predominantly in those with high-risk genotypes, QTc ≥550 ms or very early presentation. MAEs were rare in LQT1-3 with QTc <500 ms. Foetal/neonatal bradycardia (5.1%) correlated with high-risk genotypes and adverse outcomes. ICDs were implanted in 33 children (8.9%); 10 (30%) received appropriate therapies, and 8 (24%) experienced complications. Left cardiac sympathetic denervation was performed in 33 (8.9%), mainly high-risk patients, and was associated with >80% arrhythmia-free survival without major complications. CONCLUSIONS: In this nationwide paediatric LQTS cohort, MAEs were uncommon and clustered in children with malignant genotypes, markedly prolonged QTc and very early presentation, particularly foetal or neonatal bradycardia. These data support the current genotype and QTc-guided management strategy, with beta-blockers as the cornerstone therapy and selective use of left cardiac sympathetic denervation and ICDs in high-risk profiles.
引用
- Perin F, Cartón AJ, Bermúdez-Jiménez FJ, et al. Paediatric long QT syndrome: clinical outcomes and therapy in the Spanish National Registry. Eur Heart J. 2026. PMID: 42466893. doi:10.1093/eurheartj/ehag513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。